Elisabeth A Lambert1,2, Carolina I Sari1, Nina Eikelis1,2, Sarah E Phillips1,2, Mariee Grima1, Nora E Straznicky1, John B Dixon3,4, Murray Esler1, Markus P Schlaich5, Geoffrey A Head6, Gavin W Lambert1,2. 1. Human Neurotransmitters Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia. 2. Faculty of Health, Arts and Design, Iverson Health Innovation Research Institute, Swinburne University of Technology, Hawthorn, Victoria, Australia. 3. Clinical Obesity Research Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia. 4. Department of General Practice, Monash University, Clayton, Victoria, Australia. 5. Dobney Hypertension Centre, School of Medicine, Royal Perth Hospital Unit, University of Western Australia, Perth, Western Australia, Australia. 6. Neuropharmacology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Abstract
OBJECTIVE: Because sympathetic nervous system activity plays a detrimental role in metabolic and cardiovascular health, this study compared the effects of a centrally acting sympatholytic agent, the effects of a weight loss (WL) program using a low-calorie diet, and the effects of a combination of both. METHODS:Young (18-30 years) male subjects with overweight (BMI > 25 kg/m2 ) were allocated to a WL program (n = 10), a moxonidine treatment course (M; n = 10, 0.4 mg/d), a combination of both (WL + M; n = 11), or to a control (C) group (n = 6) for 6 months. Muscle sympathetic nerve activity (MSNA), endothelial function, renal function (Cockcroft-Gault formula), and the metabolic profile were assessed before and after intervention. RESULTS: WL occurred in the WL and WL + M groups (-7.6 ± 1.9 kg, P < 0.001 in both). MSNA and systolic blood pressure decreased similarly in the WL, M, and WL + M groups (by ∼10 bursts/min, P < 0.001, and by ∼9 mm Hg, P < 0.05). All other parameters for the WL, C, and M groups remained unchanged. In the WL + M group, decreased total cholesterol (-0.78 ± 0.23 mmol/L, P < 0.001), decreased low-density lipoprotein cholesterol (-0.49 ± 0.16 mmol/L, P < 0.01), decreased insulin (-6.5 ± 2.8 mmol/L, P < 0.05), and attenuated glomerular hyperfiltration (-19 ± 5 mL/min, P < 0.01) occurred. CONCLUSIONS: The combination of moxonidine with a WL program has beneficial effects on aspects of the metabolic profile and end organ damage in young males with overweight.
RCT Entities:
OBJECTIVE: Because sympathetic nervous system activity plays a detrimental role in metabolic and cardiovascular health, this study compared the effects of a centrally acting sympatholytic agent, the effects of a weight loss (WL) program using a low-calorie diet, and the effects of a combination of both. METHODS: Young (18-30 years) male subjects with overweight (BMI > 25 kg/m2 ) were allocated to a WL program (n = 10), a moxonidine treatment course (M; n = 10, 0.4 mg/d), a combination of both (WL + M; n = 11), or to a control (C) group (n = 6) for 6 months. Muscle sympathetic nerve activity (MSNA), endothelial function, renal function (Cockcroft-Gault formula), and the metabolic profile were assessed before and after intervention. RESULTS: WL occurred in the WL and WL + M groups (-7.6 ± 1.9 kg, P < 0.001 in both). MSNA and systolic blood pressure decreased similarly in the WL, M, and WL + M groups (by ∼10 bursts/min, P < 0.001, and by ∼9 mm Hg, P < 0.05). All other parameters for the WL, C, and M groups remained unchanged. In the WL + M group, decreased total cholesterol (-0.78 ± 0.23 mmol/L, P < 0.001), decreased low-density lipoprotein cholesterol (-0.49 ± 0.16 mmol/L, P < 0.01), decreased insulin (-6.5 ± 2.8 mmol/L, P < 0.05), and attenuated glomerular hyperfiltration (-19 ± 5 mL/min, P < 0.01) occurred. CONCLUSIONS: The combination of moxonidine with a WL program has beneficial effects on aspects of the metabolic profile and end organ damage in young males with overweight.
Authors: Elisabeth A Lambert; Sarah Phillips; Regina Belski; Ainura Tursunalieva; Nina Eikelis; Carolina I Sari; John B Dixon; Nora Straznicky; Mariee Grima; Geoffrey A Head; Markus Schlaich; Gavin W Lambert Journal: Front Physiol Date: 2017-11-09 Impact factor: 4.566
Authors: Soulmaz Shorakae; Elisabeth A Lambert; Eveline Jona; Carolina Ika Sari; Barbora de Courten; John B Dixon; Gavin W Lambert; Helena J Teede Journal: Front Physiol Date: 2018-10-25 Impact factor: 4.566
Authors: Revathy Carnagarin; Kearney Tan; Leon Adams; Vance B Matthews; Marcio G Kiuchi; Leslie Marisol Lugo Gavidia; Gavin W Lambert; Elisabeth A Lambert; Lakshini Y Herat; Markus P Schlaich Journal: Int J Mol Sci Date: 2021-04-19 Impact factor: 5.923
Authors: Carolina Ika Sari; Nina Eikelis; Geoffrey A Head; Markus Schlaich; Peter Meikle; Gavin Lambert; Elisabeth Lambert Journal: Front Physiol Date: 2019-09-18 Impact factor: 4.566